KFAS
IONS icon

Keating Financial Advisory Services’s Ionis Pharmaceuticals IONS Stock Holding History

Keating Financial Advisory Services’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.98K Sell
88
-2
-2% -$151 ﹤0.01% 1397
2026
Q1 		$6.76K Buy
90
+74
+463% +$5.84K ﹤0.01% 1283
2025
Q4 		$1.27K Buy
+16
New +$1.21K ﹤0.01% 1726

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Keating Financial Advisory Services's IONS Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Ionis Pharmaceuticals (IONS) stake by 2.2% in Q2 2026, selling an estimated $151 and leaving 88 shares worth $6.98K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Keating Financial Advisory Services first reported a position in IONS in Q4 2025 and has held it in 3 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Keating Financial Advisory Services held 88 shares of Ionis Pharmaceuticals worth $6.98K as of Q2 2026.
  • Keating Financial Advisory Services sold 2 Ionis Pharmaceuticals shares in Q2 2026, an estimated $151.
  • Ionis Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1397 holding.
  • Keating Financial Advisory Services first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.